<?xml version="1.0" encoding="UTF-8"?>
<p id="para400">285 (25%) of 1137 patients in the lenalidomide group and 328 (39%) of 834 patients in the observation group had second disease progression or died. Median progression-free survival 2 was 64 months (95% CI 57–not reached) with lenalidomide and 45 months (41–50) with observation (HR 0·65 [95% CI 0·56–0·77]; p&lt;0·0001; 
 <xref rid="fig3" ref-type="fig">figure 3</xref>).
</p>
